| Cat# | DIA-842 |
| Descriptions | Recombinant SARS-CoV-2 3CL Protease (rSARS-CoV-23CLProtease) is the main cysteine protease of SARS-CoV-2 that specifically cleaves viral polyproteins at conserved glutamine-containing sites, is a core target for antiviral drug screening, and is widely used for inhibitor development and virology mechanism research. |
| Applications | Recombinant SARS-CoV-2 3CL Protease (rSARS-CoV-23CLProtease) is applied in antiviral drug screening detection kits and viral protease activity assay reagent development. |
| CAS No. | 6261-06-1816 |
| Enzyme Source | Escherichia coli |
| Form | White lyophilized powder | Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0, with 5% Trehalose, 0.02% Tween-20. |
| Reaction | The 3CL protease (aka 3CLpro, Mpro or "Main" Protease) from the human SARS-CoV-2 coronavirus is a C30-type cysteine protease. 3CLpro activity is required to process the viral polyprotein into functional, mature subunits. Along with the CoV-2 Papain-Like Protease, 3CLpro presents an attractive target for therapeutic intervention for COVID-19. |
| Activity Definition | Test in process. |
| Purity | > 97% by SDS-PAGE |
| Package | 50 μg, 100 μg |
| Download Datasheet: |  |
